Nordic Pharma Announces European Launch of Lacrifill® Canalicular Gel - Takeaways - MDSpire

Nordic Pharma Announces European Launch of Lacrifill® Canalicular Gel

Novel therapy for dry eye market

  • February 10, 2026

  • 2 min

Share

  • 1

    Nordic Pharma has launched Lacrifill®, a new therapy for dry eye, in the European market following CE mark approval in 2025.

  • 2

    Lacrifill® is a cross-linked hyaluronic acid gel that temporarily blocks tear drainage to enhance tear film preservation.

  • 3

    The gel provides a full fill of the canalicular system, offering long-lasting effects for up to six months.

  • 4

    Dry eye disease affects up to 30% of the European population and poses challenges for patients undergoing ocular surgeries.

  • 5

    Lacrifill® aims to optimize ocular surface health pre-and post-operatively, improving surgical outcomes and patient satisfaction.

Original Source(s)

Nordic Pharma Announces European Launch of Lacrifill® Canalicular Gel

  • February 10, 2026

Related Content

Computational pharmacovigilance of Lifitegrast in dry eye disease using machine learning and network toxicology

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

Wogonoside alleviates hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells via PI3K/AKT signaling